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Does the European Single Market Exist in the Era 
of a Coronavirus Pandemic? The Case of Intra 
and Extra-EU Trade in COVID-19-related Products
Abstract
The COVID-19 pandemic has been an extraordinary event for the EU 
Member States and a period wherein EU legislation and the effi ciency of 
EU institutions have been put to the test. The crisis triggered by the de-
cisions made by governments in Europe (which were motivated by their 
wishes to protect the health and lives of their peoples and to satisfy the rapid 
demand for drugs, personal protective equipment, and medical devices) dis-
rupted market forces. Although most of these measures were based on both 
domestic and EU legislation, they seriously hindered the smooth function-
ing of the EU Single Market, including the free movement of goods. This 
paper aims to fi nd out whether EU legislation succeeded in coping with 
the challenges triggered by COVID-19 in the fi eld of international trade 
and whether measures taken by the European Commission with a view to 
complying with the rules of the EU Single Market adequately took care of 
the needs stemming from the COVID-19 outbreak and whether it properly 
tackled protectionist instruments adopted by the Member States. We have 
focused on international trade and the free movement of goods within the 
EU as they both constitute the cornerstone of EU economic integration. 
We found that although EU legislation was not tailored specifi cally for the 
times of a COVID-19 pandemic, in the area of international trade (including 
intra-EU trade), as well as in the fi eld of placing goods on the market, it pro-
vided extraordinary solutions. Apparently, the explanations and guidelines 
provided by the Commission have limited the scope of individual protec-
tionist and interventionist actions of the Member States.
Keywords: Single European Market, Physical Barriers, Border Control, 
Technical Barriers, COVID-19
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Introduction
It is without doubt that the COVID-19 pandemic was an extraordinary 
phenomenon that occurred in the spring of 2020 in the European Union. 
Faced with a threat to the lives and health of their peoples, practically all 
governments of the EU Member States decided to put restrictions and 
bans in place. Although most of these measures were based on both do-
mestic and EU legislation, they seriously hindered the smooth function-
ing of the EU Single Market, including the free movement of goods. As 
a result, they have compounded the problems of businesses which, on the 
face of it, were protected by protectionist instruments. At the same time, 
the European Commission published a series of guidelines addressed at 
companies and public authorities in the hope of reducing the negative ef-
fects of the pandemic and, indirectly, of Member States’ actions. 
This paper aims to fi nd out whether the EU legislation succeeded in 
coping with the challenges triggered by COVID-19 in the fi eld of inter-
national trade and whether the measures taken by the European Com-
mission with a view to complying with the rules of the EU Single Market 
adequately took care of the needs stemming from the COVID-19 outbreak 
and properly tackled protectionist instruments adopted by the Member 
States. We have focused on international trade and the free movement of 
goods within the EU as both constitute the cornerstone of EU economic 
integration. To this end, we have analysed the restrictions and barriers in-
troduced by the Member States to tackle the COVID-19 pandemic, as well 
as the measures applied by the European Commission to meet the same 
goals ensuring, at the same time, the integrity of the single market and EU 
solidarity. Therefore, we have analysed restrictions on cross-border trade 
introduced by the EU Member States, limitations on extra-EU exports 
and facilitation measures in extra-EU imports applied by the European 
Commission as well as its liberalising approach to technical requirements 
on placing CE-marked goods on the EU’s Internal Market. We focused 
our research only on COVID-19-related products: a) COVID-19 test kits 
(instruments and apparatus used in diagnostic testing), b) protective gar-
ments and the like, including PPE, c) disinfectants and sterilization prod-
ucts, d) oxygen therapy equipment, e) medical devices and equipment, 
f) medical consumables, and g) medical vehicles and furniture. In order 
to present a more comprehensive economic outlook of the consequences 
of the selected measures applied due to the COVID-19 pandemic, we ana-
lysed changes in intra and extra EU-27 trade in selected goods. The time 
frame for the research covers the fi rst stage of COVID-19 in the EU, i.e., 
the period between March and September 2020.
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Restrictions on Cross-border Trade
The free movement of goods, one of the four freedoms set out in the 
Treaty, is the cornerstone of the European Single Market. It was imple-
mented to legitimise the abolition of the then existing traditional barri-
ers to trade, as well as physical (internal border controls) and technical 
(diverse technical requirements) barriers.1 In 2016 it was estimated that 
the removal of controls on one internal border is equivalent to the reduc-
tion of a tariff by 0.7 percentage points, while establishing an EU customs 
union and the single market is equivalent to duties of 17.82% for trade in 
goods.2 Thus, one needs to note that any restriction on trade increases the 
costs borne by companies and consumers. This was exactly the case as re-
gards the COVID-19 outbreak when the Member States adopted restric-
tions on the export of specifi c goods from their respective territories and 
went on to restore border controls (those which especially affected people 
but which also had consequences for transported goods).
When it comes to exports (including intra-EU trade), the ban was 
adopted by the Member States because of major shortages not only of 
personal protective equipment (PPE) and medical products, but also of 
COVID-19 related drugs. Since all custom duties, quantitative restric-
tions and measures have a similar effect on customs duties and quantita-
tive restrictions, along with the fact that physical and technical barriers 
to intra-EU movement of goods had been abolished as part of the free 
movement of goods, such measures were allowed as the so-called techni-
cal regulations introduced to serve the public interest.3 In this very case, 
‘technical regulation’ means not only technical specifi cations but also so-
lutions prohibiting the manufacture, import, and marketing of products. 
The Directive establishes a notifi cation procedure to be followed before 
such regulations enter into force so as to be able to assess their compat-
1  A.A. Ambroziak, Handlowe skutki ewolucji prawa swobodnego przepływu to-
warów. Bilans dwudziestolecia istnienia rynku wewnętrznego UE, “Studia Europejskie”, 
no. 65(1)/2013, pp. 75–100; A.A. Ambroziak, New Challenges for the Free Movement 
of Goods within the Internal Market of the European Union, in: Introduction to Euro-
pean Studies: A New Approach to Uniting Europe, eds. D. Milczarek, A. Adamczyk, 
K. Zajączkowski, Center of Europe, University of Warsaw, Warsaw 2013.
2  G. Felbermayr, J. Gröschl, T. Steinwachs, Trade costs of border controls in the 
Schengen area, VOX EU, CEPR, 2016, https://voxeu.org/article/trade-costs-border-
controls-schengen-area (access 31.12.2020).
3  Directive (EU) 2015/1535 of the European Parliament and the Council of 9 Sep-
tember 2015 laying down a procedure for the provision of information in the fi eld of 
technical regulations and of rules on Information Society services (codifi cation), OJ 
2015 L 241/1, 17.09.2015.
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ibility with EU legislation. It is intended to eliminate potential barriers to 
trade and their negative effects already at an early stage. 
The notifi cation procedure provides for a so-called standstill clause 
which postpones the adoption of draft technical regulations for three 
months from the date of the receipt of a draft by the Commission. Within 
this period the Commission is expected to assess the new legal measure 
and, if the assessment is negative, it engages in a dialogue with the Mem-
ber State concerned to eliminate potential non-compliance. During the 
COVID-19 outbreak in the spring of 2020, the Member States did not 
have a particularly long time to act which is why they decided to immedi-
ately adopt and implement new legal solutions without any consultations 
citing “urgent reasons occasioned by serious and unforeseeable circum-
stances relating to the protection of public health or safety.”
Over the researched period, i.e. between March and September 2020, 
Member States notifi ed several hundred technical regulations related to 
COVID-19 in total. However, only around a dozen of them directly con-
cerned intra-EU trade. With regard to COVID-19-related products, new 
regulations provided for, among others, a ban on exports of PPE as well as 
drugs (Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, 
France, Germany, Greece, Hungary, Latvia, the Netherlands, Poland, Ro-
mania, Slovakia, and Spain), authorising national drug agencies to oblige 
manufacturers, importers, and distributors to build up stocks of specifi c 
products (Denmark), selling these products in specifi c quantities and at 
specifi c prices to fi ght speculation (Denmark, the Czech Republic, France, 
Germany, and Slovenia), taking over products (requisitioning), carrying 
out supplies and distribution through appointed entities (France, Den-
mark, and Finland), restrictions on drug prescriptions (Estonia, Finland, 
and France), a reduction of VAT rates on specifi c PPE products (France), 
changes in requirements concerning the placing on the market of drugs, 
diagnostic products, medical devices, and PPE (France, Hungary, Italy, 
and Belgium), as well as restrictions on public procurement and its re-
focus (Sweden).4
In response to the above actions undertaken by the Member States, the 
European Commission already in early April 2020 adopted guidelines on 
drug supplies during the COVID-19 pandemic. In these guidelines the 
4  TRIS Technical Regulation Information System based on the Directive (2015), 
https://ec.europa.eu/growth/tools-databases/tris/en/search/ (access 31.12.2020); WTO, 
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Commission clearly stated that total bans on the export of medicines are 
not compliant with the Treaty and impede the functioning of the single 
market. In addition, it was rightly observed that the artifi cial stockpiling 
of medicines triggers uncontrolled increases of stocks which may lead 
to serious shortages in places where these medicines are really needed. 
Notably, the Commission unambiguously highlighted that no country 
is self-suffi cient in the raw materials, intermediates, APIs, and fi nished 
medicines required to ensure a well-functioning healthcare system.5 Obvi-
ously, it attempted to make the governments of the Member States aware 
that strength lies in solidarity and not in adopting protectionist measures 
that, on the face of it, partly protect national interests. 
Besides, in order to mitigate any negative consequences of restrictions 
on the free movement of people as a result of the restoration of border 
controls introduced by the Member States, a decision was taken to imple-
ment so-called Green Lanes (for road transport, checks at border-crossing 
points on the TEN-T Network were to take no more than 15 minutes) 
along with some facilitations in Air Cargo Operations. These solutions 
were intended to ensure the smooth transport of critical products such as 
food, medical supplies and PPE, and other products which are vital for 
the functioning of sensitive supply chains. The Commission argued that 
all vehicles in cargo transport that are used to transport, inter alia, the 
above-mentioned products, should be permitted to operate at all times. 
This was important because some Member States did not exempt cargo 
transport from those bans on the movement of people (it concerned spe-
cial restrictions on cargo workers which de facto prevented them from 
carrying out normal operations.6
One should assume that the above-listed restrictive measures put in place 
to ensure the health and safety of citizens had some impact on the intra-EU 
trade of products covered by the restrictions. The value of all COVID-19-
related products in the fi rst wave of the pandemic (between March and 
September 2020) reached EUR 134.6 bn compared to EUR 121.9 bn with-
in a comparable period of 2019 and EUR 116.6 bn in 2018. The increase 
stemmed mainly from trade in medical consumables, COVID-19 test kits 
5  Guidelines on the optimal and rational supply of medicines to avoid shortages 
during the COVID-19 outbreak, OJ 2020 C 116 I/01, 8.04.2021.
6  Communication from the Commission on the implementation of the Green 
Lanes under the Guidelines for border management, measures to protect health and 
ensure the availability of goods and essential services , OJ C 96 I/1, 24.03.2020, Guid-




Studia Europejskie – Studies in European Affairs, 1/2021
and, to a lesser extent, medical devices, and protective garments including 
PPE. In March, when COVID-19 reached Europe, the value of trade in 
both medicines and tests clearly increased and after restrictions were intro-
duced by the Member States. In the following months, it returned to pre-
pandemic levels. Thus, after an initial 2–3 months of uncertainty, despite 
the maintenance of restrictions which were visible in the European Single 
Market in particular in April, the overall size and structure of trade in indi-
vidual groups of products did not change substantially compared to 2019.
Figure 1. Intra EU-27 trade in COVID-19-related products in 2020
Source: Eurostat.
Sudden shortages of goods in domestic markets and a considerable in-
crease in demand have contributed to substantial price increases. To capture 
the essence of this relationship, we compared the value and volume of trade 
in the subsequent months of 2020 compared to 2019. An indicator greater 
than 1 means that the relationship between the value of intra-EU exports to 
its volume (unit price) was greater in 2020 compared to 2019 (Table 1). The 
highest increase in the average unit price calculated this way was reported 
for COVID-19 test kits (an incredible increase of 79% in July 2020 com-
pared to 2019) and oxygen therapy equipment (which increased by 34% as 
of June). At the same time, unit prices of medical devices and equipment, 
not unlike protective garments including the PPE, along with disinfectants 
and sterilization products did not change substantially. Even though for the 
latter a signifi cant increase was reported in May 2020 compared to 2019, it 
was compensated for with major reductions in the following months.
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Table 1. Changes in prices of COVID-19-related products in intra-EU trade 


















A – COVID-19 
Test kits 0.71 1.14 1.38 1.14 1.42 1.20 1.79 1.17 1.42
B – Protective 




1.08 1.06 1.05 1.13 1.24 1.13 1.11 1.27 1.14
D – Oxygen the-
rapy equipment 0.98 1.02 1.10 1.14 1.21 1.34 1.29 1.28 1.21
E – Medical de-
vices and equip-
ment
1.20 1.03 0.80 0.94 0.93 0.88 0.96 0.95 0.93
F – Medical 
consumables 1.08 1.16 1.25 1.23 1.07 0.99 1.11 1.34 1.03
G – Medical 
vehicles and 
furniture
0.97 1.10 0.98 0.96 1.05 0.94 0.91 0.92 0.94
Source: The author’s own calculations based on Eurostat data.
Thus, we may conclude that despite the pandemic and significant 
increases in demand which triggered market shortages of selected 
COVID-19-related products, intra-EU trade continued. Hence, restric-
tions introduced by the Member States, though mitigated and civilised 
by the EU regulations seeking to ensure the transparency of adopted 
measures, did not totally suspend intra-EU trade in these products. Nev-
ertheless, they might have slightly intensifi ed market pressure exerted by 
surplus demand and supply shortages on temporary price increases which 
were subsequently compensated – albeit gradually – by the market through 
increases in their production and price decreases in intra-EU trade.
Restrictions on Exports Outside the EU
On grounds of the EU’s Common Commercial Policy, trade between 
the EU and third countries is regulated by the provisions of art. 206 and 
207 of the Treaty on the Functioning of the European Union. The same 
provisions constitute the legal base for the Regulation of 2015 on common 
rules for exports. It provides for the possibility to deploy, among others, 
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protective measures in exports of concrete products outside the EU to 
prevent a critical situation arising due to a shortage of essential prod-
ucts.7 It became the basis for the issuing of an implementing Regulation 
by the Commission in March 2020, which provides for the need to apply 
for authorisation for the export of selected types of PPE to competent 
authorities of a Member State where the exporter is established.8 With-
out such authorisation, exports outside the EU were prohibited. If PPE 
were located in a Member State other than the one where the application 
for export authorisation had been made, all the Member States involved 
should be able to make known either their consent or refusal to exports 
from their territories outside EU borders. Remarkably, the Commission 
stressed that some quantities of specifi c products could be exported under 
specifi c circumstances, such as ensuring aid to third countries. However, 
the fi nal decision rested with a given Member State.
Despite the above discussed provisions, interested Member States 
and countries of the European Economic Area forced the Commission to 
quickly exempt Norway, Iceland, Lichtenstein, and Switzerland from the 
ban invoking the special relations these countries had developed within 
the internal market; for the Faroe Islands, Andorra, San Marino, Vatican 
City State, and overseas territories, the argumentation was based on their 
specifi c dependence on metropolitan supply chains of the EU Member 
States.9 That shows the power of the EU Single Market whose regulations 
are also binding in the EEA countries which, nevertheless, are treated as 
third countries by the EU common commercial policy. The above-men-
tioned provisions were initially introduced for 6 weeks and, by the end of 
that period, were expanded for further 30 days. Notably, acting apparent-
ly under international pressure, the Commission stressed that “it is not 
the intention of the Union to restrict exports any more than absolutely 
necessary, and the Union also wishes to uphold the principle of interna-
tional solidarity in this situation of a global pandemic” and “an export 
authorisation system should remedy or prevent situations of shortages of 
essential products within the borders of the Union.” Moreover, the Regu-
lation provides for an authorisation procedure, not a total ban on justifi ed 
7  Regulation of the European Parliament and of the Council No 2015/479 of 11 
March 2015 on common rules for exports, OJ L 83/34, 27.03.2015.
8  Commission Implementing Regulation 2020/402 of 14 March 2020 making the 
exportation of certain products subject to the production of an export authorisation, 
OJ L 2020 77I/1, 15.3.2020.
9  Commission Implementing Regulation 2020/426 of 19 March 2020 amending 
Implementing Regulation 2020/402 making the exportation of certain products sub-
ject to the production of an export authorisation, OJ 2020 L 84I/1, 20.3.2020.
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exports of the products in question. Member States should positively con-
sider granting authorisation in cases when exports are intended for State 
bodies, public institutions, and bodies governed by the public law and in 
charge of distributing or making PPE available to persons affected by or at 
risk from COVID-19 or involved in combating the COVID-19 outbreak. 
An additional argument in favour of granting authorisation was sought 
in offering support to what the World Trade Organisation was doing and 
coordinated actions undertaken at the EU level in crisis situations un-
folding in third countries.10
The new Regulation added Gibraltar and the Western Balkans to the 
earlier extended geographical scope of the derogation from the duty to ob-
tain the authorisation (Albania, Bosnia and Herzegovina, Kosovo, Mon-
tenegro, Northern Macedonia, and Serbia) as candidate countries for EU 
membership and/or covered by special partnership arrangements; it also 
reminded us that the United Kingdom still had to be treated as a Member 
State, not as a third country.
The above solutions meant that, on the one hand, the Commission, 
despite pursuing the Common Commercial Policy, enabled the govern-
ments of the Member States granting individual support to non-EU coun-
tries with which they had specifi c political and economic links. On the 
other hand, it encouraged the Member States to relax trade restrictions 
in trade with third countries being aware of both disrupted value chains 
and supplies, as well as of consequences in other economic areas. Thus, it 
is not hard to imagine similar restrictions being put in place or straight-
forward bans on the exports of intermediates or raw materials necessary 
to produce fi nal products in the EU. We also need to note the negative 
effects of a ban on trade. According to Evenett, during the crisis period, 
export limits raised the level and volatility of world prices while doing lit-
tle to depress domestic prices which were driven, in part, by other factors. 
Moreover, as health professionals are on the front lines in the fi ght against 
COVID-19 and to reduce the risk to themselves of getting sick - they need 
protective medical kits, while export bans on masks, as PPE, erode the 
capability of trading partners to cope with the spread of COVID-19.11 At-
tention should also be paid to several consequences of any implemented 
restrictions: limited interest in future export production, an increased 
burden on Member States’ budgets forced to artifi cially increase produc-
10  Commission Implementing Regulation 2020/568 of 23 April 2020 making the 
exportation of certain products subject to the production of an export authorisation, 
OJ L 2020 129/7, 24.4.2020.
11  S.J. Evenett, Tackling COVID-19 together. The trade policy dimension, Global 
Trade Alert, 2020.
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tion, a loss of trust in international trade at political and business levels, 
as well as the introduction of retaliatory measures by suffering countries.
One might assume that the introduced restrictions should signifi -
cantly reduce the extra-EU exports of COVID-19 related products. Over 
a period of seven months during the fi rst wave of the pandemic, the EU 
exported these products worth almost EUR 33 bn in 2020 while in the 
analogous period of 2019 exports amounted to EUR 28.8 bn, and in 2018 
to EUR 23 bn. This increase was mostly due to the exports of products 
such as COVID-19 test kits, oxygen therapy equipment, as well as dis-
infectants, and sterilization products. On the other hand, drops (expe-
rienced mostly in April following a signifi cant increase in March 2020) 
were reported in medicines, protective garments including PPE, medi-
cal devices and equipment, medical vehicles, and furniture, i.e. products 
directly covered by restrictions in the EU (Figure 2). The structure of 
extra-EU exports and trends more or less overlapped with intra-EU trade 
which seemed to derive from both domestic limitations and restrictions 
put in place at the EU level. What is noteworthy is that in many cases the 
problem concerned authorisation requirements, not an absolute ban on 
exports of specifi c goods which gave room for manoeuvre to State bodies 
and companies.
Figure 2. Extra EU-27 export of COVID-19-related products in 2020
Source: Eurostat.
Given the extra-EU export value-to-volume rate in the years 2019–
2020, we can say that, in principle, products offered by the EU were not 
signifi cantly more expensive than before the pandemic. Exceptions, only 
in individual months, cover the COVID-19 tests and disinfectants (Ta-
ble 2). Thus, it means that the imposed restrictions did not translate so 
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much on price increases as in intra-EU trade. World competition and the 
global market, despite the pandemic, did not permit the using of infl ated 
prices for products the supply of which, sometimes with delays, satisfi ed 
the demand.
Table 2. Changes in the prices of COVID-19-related products exported 


















A – COVID-19 
Test kits 0,94 0,76 1,01 0,67 1,83 1,34 1,15 1,08 1,09
B – Protective 




0,96 1,18 0,97 1,12 1,12 1,41 1,04 1,33 0,98
D – Oxygen the-
rapy equipment 1,01 0,89 1,21 1,14 0,97 1,05 1,24 1,11 1,13
E – Medical 
devices and 
equipment
0,99 0,83 0,92 1,14 0,87 0,94 0,82 0,89 0,85
F – Medical 
consumables 1,20 1,19 1,06 0,86 0,86 0,92 0,87 0,79 0,74
G – Medical 
vehicles and 
furniture
0,80 1,07 1,22 1,11 1,21 1,06 0,98 1,09 1,09
Source: The author’s own calculations based on Eurostat data.
Facilitation of Imports to the EU
As regards imports from third countries, many EU Member States 
(namely Italy on 19 March 2020, France on 21 March 2020, Germany and 
Spain on 23 March 2020, Austria, Cyprus, the Czech Republic, Estonia, 
Greece, Croatia, Lithuania, the Netherlands, Poland, Portugal, and Slov-
enia on 24 March 2020, Belgium, Bulgaria, Denmark, Finland, Hungary, 
Ireland, Luxembourg, Latvia, Romania, Slovakia, and the United King-
dom on 25 March 2020, and Sweden and Malta on 26 March 2020) duly 
fi led for exemption from customs duties and VAT on imports of some 
COVID-19-related products. In this case the Commission, within the 
framework of the Directive and a Regulation on a Community system 
of reliefs from customs duty (2009), lifted these duties and taxes for the 
period starting on 30 January and running until 31 July 2020 for prod-
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ucts intended for free-of-charge distribution to people affected or at risk 
from the COVID-19 pandemic or engaged in combating it provided these 
goods were owned by public institutions.12
The reduction of customs duties introduced by the EU was appar-
ently important for selected groups of COVID-19-related products. For 
medical consumables, medical devices, and test kits, EU custom duties 
already amounted to 0%. However, in other product groups, with a few 
exceptions, custom duty rates were much higher and reached 12% on, 
e.g., textile face masks (without a replaceable fi lter or mechanical parts) 
including surgical masks and disposable face masks made of non-woven 
textiles, protective garments for surgical/medical use made up of felt or 
nonwovens, as well as alcohol-based disinfectants.
Table 3. Tariff duties imposed on selected COVID-19-related products by 
the EU (1 March 2020)
Categories Tariff
A – COVID-19 Test kits/ Instruments and ap-
paratus used in Diagnostic Test: COVID-19 Test 
kits – Diagnostic reagents based on polymerase 
chain reaction (PCR) nucleic acid test, diagnostic 
reagents based on immunological reactions
0.0%
B – Protective garments and the like: Face and eye 
protection, gloves 0–12%
C – Disinfectants/Sterilisation products: Alcohol 
solutions 
Hand sanitizer and other disinfectant preparations
Od 19.2 EUR/hl 
do 1.00 EUR / % vol/hl 
+ 6.40 EUR / hl 
0–6.0%
D – Oxygen therapy equipment: Hydrogen perox-
ide 0–5.5%
E – Medical devices: Computed tomography, scan-
ners, extracorporeal membrane oxygenation, medi-
cal ventilators, patient monitoring devices
0.0%
F – Medical Consumables: Wadding, gauze, band-
ages, cotton sticks, syringes, with or without nee-
dles, tubular metal needles and needles for sutures, 




12  Commission, Decision 2020/491 of 3 April 2020 on relief from import duties 
and VAT exemption on importation granted for goods needed to combat the effects 
of the COVID-19 outbreak during 2020, OJ L 2020 103 I/1, 3.04.2020.
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Referring to the procedural aspects of the importation of goods, in-
cluding those of a critical nature, the Commission was much more re-
luctant. Among some simplifi cations concerning empowerment for cus-
toms representation during customs procedures in e-commerce, new ap-
plications for only essential customs decisions, along with an extension 
of the time-limit to take decisions on applications already submitted as 
well as customs debts, guarantees and payments, the Commission only 
maintained that, based on Article 127.7 Union Customs Code Customs 
(UCC), it is possible to use commercial, port or transport information 
systems for the lodging of an entry summary declaration on condition 
that such systems contain the necessary particulars. Moreover, the Com-
mission suggested, that in the case of critical goods, the UCC should 
offer a customs declaration lodged prior to the expected presentation of 
the good to customs, as well as in consecutive parts (if the shipment was 
split).13 
The above-mentioned facilitations clearly helped in partially meeting 
the demand for COVID-19 related products. From March to September 
2020, imports from non-EU countries amounted to EUR 98.5 bn com-
pared to EUR 73.4 bn in 2019 and EUR 66.2 bn in 2018. That stemmed 
primarily from more than a fourfold increase in April 2020 and an almost 
sixfold increase in May 2020 (compared to February) of imports of pro-
tective garments. Attention should be paid to the fact that custom duty 
rates for these products were reduced the most. For other products, the 
value of imports was relatively stable, save medical consumables, the val-
ue of which seriously fl uctuated in the months covered by the research of 
the fi rst months of coronavirus virus.
The above conditions are, to some extent, explained by an analysis 
of the average unit price obtained from the relationship of export val-
ue-to-volume in 2020 compared to 2019. The highest increase in the 
unit price interpreted in this way was revealed for the above-mentioned 
protective garments (the value of exports being four times higher in 
2020 compared to 2019 for a volume increase of 10–20%), disinfecting 
products, and oxygen therapy equipment (Table 4). It means that in the 
face of a substantial demand for COVID-19-related products and in the 
absence of any possibilities to satisfy the demand through EU produc-
tion, non-EU partners took advantage of the situation and signifi cantly 
13  Regulation of the European Parliament and of the Council No 952/2013 of 
9 October 2013 laying down the Union Customs Code, OJ L 2013 269/1, 10.10.2013; 




Studia Europejskie – Studies in European Affairs, 1/2021
increased prices. This trend is obviously different from the trend ob-
served in extra-EU exports.
Figure 3. Extra EU-27 import of COVID-19-related products in 2020
Source: Eurostat.
Table 4. Changes in price of COVID-19-related products imported to the 


















A – COVID-19 
Test kits 0,93 1,06 0,79 1,54 2,55 1,11 1,83 1,50 1,28
B – Protective 
garments 1,02 0,97 1,15 4,08 4,53 2,83 2,20 1,54 1,33
C – Disinfectants 
and sterilization 
products
1,17 1,22 0,83 1,38 1,78 1,63 1,40 1,75 1,53
D – Oxygen 
therapy equipment 0,84 0,84 0,99 1,44 2,05 1,92 1,11 1,12 1,27
E – Medical 
devices and 
equipment
0,93 0,95 0,97 1,07 0,91 0,95 0,90 0,95 1,01
F – Medical 
consumables 0,90 0,94 0,65 1,20 1,27 0,69 0,79 0,85 0,57
G – Medical 
vehicles and 
furniture
1,04 1,02 0,75 0,96 1,03 0,85 1,00 0,79 0,88
Source: own calculation based on Eurostat data.
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Technical Entry Requirements
Due to the COVID-19 outbreak, there was a massive redesigning of 
supply chains and a shifting in the manufacturing of economic entities 
towards the production of in demand COVID-19 related products, espe-
cially PPE. To this end, many companies decided to redesign their sup-
ply chains by launching new manufacturing lines or diversifying their 
supplier base. Placing PPE and medical devices in the EU Single Market 
is strictly regulated and scrutinised on the basis of technical harmoni-
sation.14 On the one hand, these provisions were seeking to ensure user 
safety but, for obvious reasons, implied not only an additional fi nancial 
burden but, above all, triggered conformity assessment procedures involv-
ing notifi ed bodies competent for new types of PPE15, which signifi cantly 
delayed their being placed on the market.16
14   Council Directive 89/686/EEC of 21 December 1989 on the approximation of 
the law of the Member states relating to personal protective equipment, OJ L 1989 
399/18, 30.12.1989; Regulation of the European Parliament and of the Council No 
2016/425 of 9 March 2016 on personal protective equipment and repealing Coun-
cil Directive 89/686/EEC, OJ L 85/51, 30.12.1989, and 1993 Directive 93/42/EEC of 
14 June 1993 concerning medical devices, OJ 1993 L 169/1 12.07.1993; Regulation of 
the European Parliament and of the Council No 2017/745 of 5 April 2017 on medical 
devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regu-
lation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/
EEC, OJ L 2017 117/1, 5.05.2017 respectively).
15  Not all medical devices and PPE require the intervention of notifi ed bodies. 
Firstly, the procedure covers class III, IIa, and IIb devices, as in the case of respira-
tory patient ventilators, as well as for class I devices supplied in sterile condition. 
As regards class I devices (medical face masks, gloves and overalls when supplied 
in non-sterile condition), manufacturers are obliged to perform a conformity assess-
ment themselves (also with the support of external laboratories) under their sole 
responsibility. When it comes to the PPE, the notifi ed bodies must be engaged in 
a conformity assessment for categories II and III of equipment (respiratory protection 
face masks used in the COVID-19: FFP2 or FFP3 masks) before it is placed on the 
European Single Market.
16  The PPE Regulation stresses that the manufacturer is obliged to perform 
a conformity assessment procedure. The requirement is also addressed to manufac-
turers from outside the EU, meaning the importers must ensure that the PPE placed 
by them on the market complies with the requirements set out in the Regulation of 
2016 and that there is technical documentation available for surveillance purposes. 
According to data from the Polish notifi ed body – Centralny Instytut Ochrony Pracy 
[Central Institute for Labour Protection], in order to carry out all the tests for the 
assessment of conformity with an adequate European harmonised standard for one 
type of fi ltering half masks, they need 50 such half masks and the standard deadline 
for tests is 25 days with the latter being shortened to 14 days when sample preparation 
and conditioning procedures are justifi ably simplifi ed. The net cost of testing has 
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To enable a quick increase in the supply of selected COVID-19-related 
products while maintaining high levels of safety, the European Commis-
sion issued a special recommendation on 13 March 2020,17 which intro-
duced some simplicities in placing selected PPE (such as face masks, 
gloves, protective coveralls or eye-wear protection, as well as for medi-
cal devices such as surgical masks, exploration gloves and some gowns) 
and medical devices essential for healthcare workers in the European 
Single Market. Obviously, the Recommendation has no binding effect, 
but it identifi es several areas in which the conformity procedure could be 
simplifi ed. First of all, the Commission stressed that the notifi ed bodies 
should prioritise a conformity assessment of PPE which seems an obvi-
ous requirement. However, we need to bear in mind that these bodies are 
commercial operators and neither the Commission nor national authori-
ties could impact their activities.
Manufacturing processes which rely on solutions which were provided 
by harmonised standards guaranteed that a product would be presumed 
to be in conformity with the essential requirements of the Directive and 
currently the Regulation on PPE and medical devices (an entity placing 
a product on the market is obliged to observe the minimum technical re-
quirements laid down in the regulations which specify only the potential 
risks to ensure user safety without defi ning its components or production 
modes). In its recommendation, the Commission extended the presump-
tion of conformity to other technical solutions that are not harmonised 
European standards so as to include recommendations from the World 
Health Organisation. In the Commission’s view, such technical solutions 
may be used as a source of reference, provided that they ensure the level of 
protection corresponding to that which is guaranteed by EU legislation. 
This approach made it possible to place on the market the PPE products 
not originally intended for the EU market which, if manufactured in ac-
cordance with WHO recommendations, could be marketed within the 
EU. In this case, all notifi ed bodies were obliged to immediately notify 
both the national notifying authority and other notifi ed bodies of the cer-
tifi cates issued. 
been estimated at EUR 3,300. For masks with replaceable fi lters the time of testing 
is shortened to 7 days while for medical face masks it is extended to 30 days at a cost 
of EUR 2,300 (CIOP, Komunikat nr 1 w sprawie badania i oceny zgodności środków 
ochrony dróg oddechowych, odzieży ochronnej oraz środków ochrony oczu i twarzy 
w kontekście działań prewencyjnych związanych z pandemią COVID-19, 19 marca 
2020, update 9 września 2020).
17  Commission Recommendation No 2020/403 of 13 March 2020 on conformity 
assessment and market surveillance procedures within the context of the COVID-19 
threat, OJ L 2020 79 I/1, 16.03.2020.
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This was a breakthrough in the practice of technical harmonisation to 
date. Therefore, the Commission indicated in its recommendation that 
the relevant market surveillance authorities in the Member States should, 
as a matter of priority, focus on PPE and medical devices that could pose 
a serious risk to the health and safety of their intended users.
At the same time, the Commission enabled market surveillance au-
thorities in the Member States to use their superior position by allowing 
them to authorise the making available of PPE and medical devices on 
the EU market for a limited period of time along with where certain con-
formity procedures laid down in the relevant legislation, including the 
affi xing of the CE marking, have not been completed. This meant that 
where traders, in cooperation with notifi ed bodies, have not carried out 
the prescribed conformity assessment procedures, national market sur-
veillance authorities, through their laboratories, could do so. This also ap-
plied to the placing on the market of PPE and medical devices purchased 
by the governments of Member States directly by government agencies 
or State-owned enterprises. In the latter case, the Commission allowed 
PPE products to be purchased without a CE marking by the competent 
authorities of the Member States, but only for healthcare professionals for 
the duration of the COVID-19 crisis. 
The above meant that PPE products fully non-compliant with the es-
sential requirements of the relevant EU directives and regulations could 
be imported into the EU. The lack of any enforcement of such require-
ments (even temporarily and for a specifi c group of end-users) illustrates 
the dramatic situation on the EU market and the insuffi cient supply of 
PPE as a basic solution to limit the spread of COVID-19. Of note, the 
Regulation of 2017 provided for a derogation from the conformity assess-
ment procedure for medical devices. It was motivated by public health, 
patient safety or health-based premises; those which were clearly fulfi lled 
by the COVID-19 pandemic. Under such circumstances, the Commission 
could, through the implementing acts, extend for a limited period of time 
the validity of an authorisation granted by a Member State to the territory 
of the Union and set the conditions under which the device may be placed 
on the market or put into service. Thus, one might say that although the 
Commission has made the system of placing goods on the market slightly 
more fl exible, especially with regard to PPE, it nevertheless did not go be-
yond the restrictive framework of technical harmonisation rules and cer-
tain facilitations were copied after solutions had been previously adopted 
for similar (medical) products.
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Conclusions
The COVID-19 pandemic has been an extraordinary event for the EU 
Member States and a period when EU legislation and the effi ciency of EU 
institutions have been put to the test. The crisis triggered by the decisions 
made by governments in Europe as well as in other parts of the world 
(motivated by the wish to protect the health and lives of their peoples and 
to satisfy the rapid demand for drugs, personal protective equipment, and 
medical devices) disrupted market forces. The lack of balance between 
supply and demand was, to some extent, deepened by the chaotic actions 
of decision-makers who, instead of looking for common solutions to prob-
lems, decided to go down a protectionist and interventionist path.
This paper aimed to fi nd out whether the EU legislation in the area 
of international trade has lived up to the challenges of COVID-19 and 
whether actions undertaken by the European Commission to comply with 
EU Internal Market rules provided an adequate response to the needs 
stemming from the COVID-19 outbreak, as well as protectionist instru-
ments applied by the Member States. Initial analyses let us believe that, 
despite some awkwardness exhibited in the fi rst weeks of pandemic in 
Europe, within the EU Internal Market the European Commission rose 
to the challenge and focused Member States’ actions on activities that 
least undermined its principles while Union legislation turned out to be 
suffi ciently fl exible. 
When it comes to intra-EU trade, the cornerstone of integration, for 
COVID-19 related products it was possible to maintain trade activities at 
a level close to the pre-pandemic period. At the outset of the pandemic, 
many Member States put restrictions on exports of selected products in-
cluding PPE, medical devices, and medical consumables. However, the 
EU system that obliges the notifi cation of such restrictions to the Euro-
pean Commission, even though it was not built with such situations in 
mind, ensured full transparency of actions. Due to that, the introduced 
restrictions were known to other partners within the EU Single Market 
and the calculated average unit prices did not increase signifi cantly. 
The situation was slightly different when it comes to extra EU-27 
trade. For exports, it can be considered that, apart from some fl uctuations 
for some products, their position has not been affected, despite a restric-
tion introduced at the EU level. This restriction, however, resulted in 
the need to apply for an authorisation for exports of selected COVID-19
-related products and was not a total ban. As a result, it was left to both 
entrepreneurs and public authorities of the Member States to decide on 
the distribution of products under special regulations. As far as imports 
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are concerned, however, they increased dramatically as regards protective 
garments, including PPE and products commonly sought after in April 
and May when European production failed to keep pace with a sudden in-
crease in demand. The answer to this was, primarily, imports from China. 
However, partners from outside the EU defi nitely took advantage of the 
shortage of some products, satisfying demand with much more expensive 
ones. In the face of this, it took two months for imports to return to pre-
pandemic levels.
Attention should also be paid to what the European Commission was 
doing within the realm of the EU Single Market. Firstly, facilitations im-
plemented with regard to meeting technical requirements and placing 
goods on the market (PPE and medical devices) were not substantially 
amended but just presented in a more transparent manner to potential 
manufacturers (which ensured rapid shifts in the production profi les of 
many European fi rms) or reasonably adjusted to suit needs (seeing WHO 
recommendations as corresponding to the technical specifi cations of the 
EU harmonised standards guaranteeing the safety of products).
In summary, it can be concluded that although EU legislation was 
not tailored specifi cally for the times of the COVID-19 pandemic, in 
the area of international trade (including intra-EU trade) as well as in 
the fi eld of placing goods on the market, it came up with extraordinary 
solutions. Apparently, the explanations and guidelines provided by the 
Commission have limited the scope of individual protectionist and in-
terventionist actions of the Member States. Such actions might have en-
sured self-suffi ciency in the supply of one of the desired products (e.g., 
PPE), but they would not have guaranteed access to other products, in-
cluding, e.g., a vaccine produced by another country which could, on 
a reciprocal basis, turn its back on the potential needy. This aspect is 
rarely considered in political decisions which have a signifi cant eco-
nomic and social impact.
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